Walleye Capital LLC Invests $1.53 Million in Savara Inc. $SVRA

Walleye Capital LLC acquired a new stake in Savara Inc. (NASDAQ:SVRA) in the second quarter, Holdings Channel reports. The institutional investor acquired 248,720 shares of the company’s stock, valued at approximately $1,532,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. raised its position in Savara by 48.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock worth $60,000 after purchasing an additional 3,205 shares during the period. Principal Financial Group Inc. bought a new stake in Savara in the first quarter worth $57,000. Russell Investments Group Ltd. boosted its position in Savara by 930.5% during the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock valued at $37,000 after buying an additional 9,463 shares during the period. Xponance LLC purchased a new stake in Savara during the fourth quarter valued at about $66,000. Finally, CIBC Bancorp USA Inc. bought a new position in shares of Savara during the third quarter valued at about $44,000. Institutional investors own 87.93% of the company’s stock.

Savara Stock Up 2.1%

Shares of NASDAQ SVRA opened at $5.38 on Friday. The firm’s fifty day moving average is $5.65 and its 200 day moving average is $5.48. Savara Inc. has a 52 week low of $2.92 and a 52 week high of $7.01. The company has a quick ratio of 13.47, a current ratio of 10.13 and a debt-to-equity ratio of 0.21. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -9.28 and a beta of 0.29.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). On average, equities research analysts expect that Savara Inc. will post -0.62 earnings per share for the current year.

Savara News Roundup

Here are the key news stories impacting Savara this week:

• Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast to a loss of $0.62 from a loss of $0.59, below the current consensus estimate of a $0.57 loss. Quarterly estimates were also reduced to losses of $0.16 for the third quarter and $0.15 for the fourth quarter.
• Negative Sentiment: The firm cut its 2027 EPS forecast to a loss of $0.37 from $0.34 and its 2028 forecast to a loss of $0.06 from $0.04, indicating continued operating losses over the next several years.
• Negative Sentiment: Longer-term estimates were also reduced: 2029 EPS was lowered to $0.09 from $0.11, while 2030 EPS was cut to $0.37 from $0.39. Although these forecasts still point to eventual profitability, the reductions weaken the near- and long-term earnings outlook.
• Neutral Sentiment: The revisions follow Savara’s recent quarterly results, in which the company reported a $0.16-per-share loss versus the $0.14 loss analysts expected. Investors may therefore remain focused on cash usage, execution and progress toward commercialization.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on SVRA. Oppenheimer initiated coverage on Savara in a report on Friday, April 24th. They issued an “outperform” rating and a $11.00 price objective on the stock. Wall Street Zen cut Savara from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Savara has an average rating of “Moderate Buy” and a consensus price target of $10.14.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.